索非布韦/达拉他韦加利巴韦林治疗丙型肝炎肝硬化的疗效及安全性
|
摘要
目的观察索非布韦/达拉他韦加利巴韦林治疗丙型肝炎肝硬化患者的疗效和安全性。方法纳入2016年5月至2017年5月就诊于昆明市第三人民医院肝病科的丙型肝炎肝硬化患者129例,给予索非布韦/达拉他韦加利巴韦林抗病毒治疗12周,治疗后随访12周,观察治疗结束12周后持续性病毒学应答(SVR12)、生化学应答、肝纤维化改善和治疗期间的不良反应。结果 129例患者HCV RNA基线水平为(5.91±1.33)lgIU/mL,治疗2周时为(1.67±1.24)lgIU/mL,治疗2周75.78%患者HCV RNA达到检测下限;治疗12周时93.44%患者HCV RNA检测不到。129例患者基线的FibroScan值为(17.57±9.86);治疗12周时的FibroScan值为(8.32±1.47)kPa(与基线相比,t=15.852,P=0.000);TBil、ALT、AST基线时分别为(24.07±18.12)μmol/L、(91.42±54.56)U/L和(81.06±40.45)U/L,治疗2周时TBil、ALT、AST均显著下降(t=2.408,P=0.017;t=11.054,P=0.000;t=12.227,P=0.000),生化学应答达100%。6例未取得SVR12的患者多因素回归分析显示,复治是独立预测因子。主要不良反应为乏力和头痛,无严重不良反应发生。结论丙型肝炎肝硬化患者索非布韦/达拉他韦加利巴韦林方案可获得较高的SVR12率和生化学应答率,肝纤维化改善明显,且具有良好的安全性。
Objective To observe the efficacy and safety of sofosbuvir/daclatasvir with ribavirin in the treatment of hepatitis C cirrhosis.Methods From May 2016 to May 2017 in our hospital,there were 129 patients with hepatitis C cirrhosis receiving 12-week sofosbuvir/daclatasvir with ribavirin therapy.Patients were followed up for 12 weeks after antiviral treatment,and sustained virologic response at week 12 post-treatment(SVR12),biochemical response,improvement of hepatic fibrosis and adverse reactions during treatment were observed.Results HCV RNA of the 129 patients was(5.9±1.33)lgIU/mL at baseline and(1.67±1.24)lgIU/mL after 2-week treatment.Among the patients,HCV RNA was undetectable in 75.78% patients after 2-week treatment and in 93.44% patients after 12-week treatment.FibroScan measurement of the patients was(17.57±9.86)at baseline and decreased to(8.32±1.47)at week 12(t=15.852,P=0.000).Serum levels of total bilirubin(TBil),alanine aminotransferase(ALT)and aspartate aminotransferase(AST)were significantly decreased at week 2 compared to those at baseline,respectively(t=2.408,P=0.017;t=11.054,P=0.000;t=12.227,P=0.000).Besides,biochemical response reached 100%.Multivariate regression analysis of 6 patients without SVR12 showed that retreatment was an independent predictor.No serious adverse reactions occurred with fatigue and headache being the main adverse reactions.Conclusion The patients with hepatitis C cirrhosis who received sofosbuvir/daclatasvir with ribavirin therapy achieved very high SVR12 rate,high biochemical response rate and significant improvement of liver fibrosis with good safety.
Objective To observe the efficacy and safety of sofosbuvir/daclatasvir with ribavirin in the treatment of hepatitis C cirrhosis.Methods From May 2016 to May 2017 in our hospital,there were 129 patients with hepatitis C cirrhosis receiving 12-week sofosbuvir/daclatasvir with ribavirin therapy.Patients were followed up for 12 weeks after antiviral treatment,and sustained virologic response at week 12 post-treatment(SVR12),biochemical response,improvement of hepatic fibrosis and adverse reactions during treatment were observed.Results HCV RNA of the 129 patients was(5.9±1.33)lgIU/mL at baseline and(1.67±1.24)lgIU/mL after 2-week treatment.Among the patients,HCV RNA was undetectable in 75.78% patients after 2-week treatment and in 93.44% patients after 12-week treatment.FibroScan measurement of the patients was(17.57±9.86)at baseline and decreased to(8.32±1.47)at week 12(t=15.852,P=0.000).Serum levels of total bilirubin(TBil),alanine aminotransferase(ALT)and aspartate aminotransferase(AST)were significantly decreased at week 2 compared to those at baseline,respectively(t=2.408,P=0.017;t=11.054,P=0.000;t=12.227,P=0.000).Besides,biochemical response reached 100%.Multivariate regression analysis of 6 patients without SVR12 showed that retreatment was an independent predictor.No serious adverse reactions occurred with fatigue and headache being the main adverse reactions.Conclusion The patients with hepatitis C cirrhosis who received sofosbuvir/daclatasvir with ribavirin therapy achieved very high SVR12 rate,high biochemical response rate and significant improvement of liver fibrosis with good safety.
引文
[1]Mohd Hanafiah K,Groeger J,Flaxman AD,et al.Global epidemiology of hepatitis C virus infection:new estimates of agespecific antibody to HCV seroprevalence.Hepatology,2013,57:1333-1342.
[2]陈新月,尚佳,杨瑞锋,等.难治性慢性丙型肝炎初治患者优化治疗后的病毒学应答率研究.中华肝脏病杂志,2015,23:412-417.
[3]Gamal N,Vitale G,Andreone P.ABT-450:a novel agent for the treatment of CHC genotype 1:focus on treatment-expedenced patients.Expert Rev Anti Infect Ther,2015,13:295-304.
[4]温先勇,唐敏,邓正华,等.中国西南三地HCV基因型的分布及临床特征.中国现代医学杂志,2016,26:42-46.
[2]陈新月,尚佳,杨瑞锋,等.难治性慢性丙型肝炎初治患者优化治疗后的病毒学应答率研究.中华肝脏病杂志,2015,23:412-417.
[3]Gamal N,Vitale G,Andreone P.ABT-450:a novel agent for the treatment of CHC genotype 1:focus on treatment-expedenced patients.Expert Rev Anti Infect Ther,2015,13:295-304.
[4]温先勇,唐敏,邓正华,等.中国西南三地HCV基因型的分布及临床特征.中国现代医学杂志,2016,26:42-46.